AIMS/HYPOTHESIS: We have examined markers of haemostasis and inflammation in men with diabetes, coronary heart disease (CHD) or both, and assessed their associations with insulin resistance in men with Type 2 diabetes. METHODS: The study was carried out in 4066 British men aged 60 to 79 years who were not on warfarin or insulin, of whom there were 426 men with prevalent Type 2 diabetes and 842 with prevalent CHD. RESULTS: Men with Type 2 diabetes were more likely to have multiple risk factors and higher levels of haemostatic and inflammatory markers than men without, irrespective of CHD status. Compared with men with CHD only, men with diabetes only showed increased levels of tissue plasminogen activator antigen, increased plasma and blood viscosity, and increased levels of coagulation factors VII, VIII and IX. They also had dyslipidaemia. In men with diabetes, increased insulin resistance (homeostasis model assessment, HOMA) was associated with increased levels of haemostatic markers and dyslipidaemia. The prevalence of CHD increased significantly with increasing tertiles of HOMA (adjusted odds ratio 1.32 [95% CI: 0.72-2.42] in the second, and 1.70 [95% CI: 0.92-3.44] in the third tertile; p=0.04 for trend). CONCLUSIONS/ INTERPRETATION: Increased insulin resistance among men with Type 2 diabetes is associated with increased prevalence of CHD and of activated haemostasis and dyslipidaemia. Reducing insulin resistance in men with diabetes may reduce their tendency to develop thrombosis and hence CHD risk.
AIMS/HYPOTHESIS: We have examined markers of haemostasis and inflammation in men with diabetes, coronary heart disease (CHD) or both, and assessed their associations with insulin resistance in men with Type 2 diabetes. METHODS: The study was carried out in 4066 British men aged 60 to 79 years who were not on warfarin or insulin, of whom there were 426 men with prevalent Type 2 diabetes and 842 with prevalent CHD. RESULTS:Men with Type 2 diabetes were more likely to have multiple risk factors and higher levels of haemostatic and inflammatory markers than men without, irrespective of CHD status. Compared with men with CHD only, men with diabetes only showed increased levels of tissue plasminogen activator antigen, increased plasma and blood viscosity, and increased levels of coagulation factors VII, VIII and IX. They also had dyslipidaemia. In men with diabetes, increased insulin resistance (homeostasis model assessment, HOMA) was associated with increased levels of haemostatic markers and dyslipidaemia. The prevalence of CHD increased significantly with increasing tertiles of HOMA (adjusted odds ratio 1.32 [95% CI: 0.72-2.42] in the second, and 1.70 [95% CI: 0.92-3.44] in the third tertile; p=0.04 for trend). CONCLUSIONS/ INTERPRETATION: Increased insulin resistance among men with Type 2 diabetes is associated with increased prevalence of CHD and of activated haemostasis and dyslipidaemia. Reducing insulin resistance in men with diabetes may reduce their tendency to develop thrombosis and hence CHD risk.
Authors: S Goya Wannamethee; Gordon D O Lowe; Peter H Whincup; Ann Rumley; Mary Walker; Lucy Lennon Journal: Circulation Date: 2002-04-16 Impact factor: 29.690
Authors: J B Meigs; M A Mittleman; D M Nathan; G H Tofler; D E Singer; P M Murphy-Sheehy; I Lipinska; R B D'Agostino; P W Wilson Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: S Neri; S Calvagno; B Mauceri; M Misseri; A Tsami; C Vecchio; G Mastrosimone; A Di Pino; D Maiorca; A Judica; G Romano; A Rizzotto; S S Signorelli Journal: Eur J Nutr Date: 2010-03-07 Impact factor: 5.614
Authors: S G Wannamethee; O Papacosta; D A Lawlor; P H Whincup; G D Lowe; S Ebrahim; N Sattar Journal: Diabetologia Date: 2011-08-23 Impact factor: 10.122
Authors: Tochi M Okwuosa; Philip Greenland; Susan G Lakoski; Hongyan Ning; Joseph Kang; Roger S Blumenthal; Moyses Szklo; John R Crouse; Joao A C Lima; Kiang Liu; Donald M Lloyd-Jones Journal: Am J Cardiol Date: 2011-03-15 Impact factor: 2.778
Authors: Katarina Lalić; Aleksandra Jotić; Nataša Rajković; Sandra Singh; Ljubica Stošić; Ljiljana Popović; Ljiljana Lukić; Tanja Miličić; Jelena P Seferović; Marija Maćešić; Jelena Stanarčić; Milorad Čivčić; Iva Kadić; Nebojša M Lalić Journal: Int J Endocrinol Date: 2015-05-18 Impact factor: 3.257